[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572515":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":26,"id":63,"slug":26,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":26,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Rush University Medical Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SG-T: sleeve gastrectomy with tirzepatide","EXPERIMENTAL","In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months after surgery they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.",[13,14],"Drug: Mounjaro","Procedure: Sleeve Gastrectomy",{"label":16,"type":17,"description":18,"interventionNames":19},"SG-A: sleeve gastrectomy alone","ACTIVE_COMPARATOR","In this study the control group (n=21) are patients who will undergo sleeve gastrectomy alone.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Mounjaro","In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"PROCEDURE","Sleeve Gastrectomy","Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.",[16,9],[33],{"name":34,"affiliation":5,"role":35},"Nicholas Skertich, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Research Administrator","CONTACT","312-942-5500","anna_t_alecci@rush.edu",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Chicago","Illinois","60612","United States",{"type":50,"coordinates":51},"Point",[52,53],-87.65005,41.85003,{"lat":53,"lon":52},[56],{"name":57,"role":39,"phone":40,"phoneExt":26,"email":58},"Sr. Clinical Research Coordinator","matthew_johnson@rush.edu",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Nicholas Skertich","Assistant Professor","100572515",false,"NCT06734273","Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss","Inclusion Criteria:\n\n* Adult 18 to 65 years of age\n* Body Mass Index \\>35 with comorbidity of Type 2 Diabetes and\u002For Hypertension and\u002For Hyperlipidemia and\u002For Obstructive Sleep Apnea OR Body Mass Index \\>40 with or without comorbidity\n* Undergoing primary sleeve gastrectomy\n\nExclusion Criteria:\n\n* Prior metabolic and bariatric surgery\n* Prior use of GLP-1 agonist\n* Prior history of pancreatitis\n* Personal\u002Ffamily history of medullary thyroid cancer or MEN type 2\n* Secondary cause of obesity\n* Any eating disorder\n* Pregnancy\u002Flactation\n* History of acute coronary syndrome or myocardial infarction\n* History of stroke\n* Hepatic dysfunction: AST\u002FALT \\>3 ULN\n* Renal dysfunction eGFR\\\u003C45ml\u002Fmin\u002F1.73m2\n* Active malignancy\n* History of diabetic retinopathy\n* History of gastroparesis","ALL","18 Years","65 Years",{"count":72,"type":73},42,"ESTIMATED","INTERVENTIONAL",[76],"EARLY_PHASE1","This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.",[79],"Obesity and Obesity-related Medical Conditions","2026-05-05",{"date":82,"type":83},"2026-05-08","ACTUAL",{"date":85,"type":83},"2025-03-10",{"date":87,"type":73},"2028-09",{"name":61,"class":6},1]